Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3652249 | 1.00 | TSHR (0.46) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL949869 | 1.00 | TSHR (0.46) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL7182170 | 1.00 | TSHR (0.46) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL7188921 | 1.00 | TSHR (0.46) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL7189741 | 1.00 | TSHR (0.46) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL489872 | 1.00 | TSHR (0.46) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL7175478 | 1.00 | TSHR (0.46) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL951294 | 1.00 | TSHR (0.46) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL7175480 | 1.00 | TSHR (0.46) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL951295 | 1.00 | TSHR (0.46) | TSHRTHRBFAAHTRPV1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140272435-A1 | ANTI-STICK SURFACE COATINGS | DESIGNER MOLECULES, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-20140020827-A1 | ANTI-BLEED COMPOUNDS, COMPOSITIONS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. (US) | 2014-01-23 | — | — | US | claimed |
| US-20110017400-A1 | ANTI-BLEED COMPOUNDS, COMPOSITIONS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. (US) | 2011-01-27 | — | — | US | claimed |
| WO-2009117729-A2 | ANTI-BLEED COMPOUNDS, COMPOSITIONS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. (US) | 2009-09-24 | — | — | WO | claimed |
| CN-113454085-B | AZA heterobicyclic inhibitors of MAT2A and methods for treating cancer | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023208092-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023193789-A1 | WEE1 DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023186065-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023138691-A1 | FUSED HETEROCYCLIC COMPOUNDS AS MODULATORS OF RAS SIGNALLING | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2023-07-27 | — | — | WO | disclosed |
| EP-4192816-A1 | COMPOUNDS AS C5AR INHIBITORS | Kira Pharmaceuticals (Suzhou) Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| CN-113912628-B | Triazine compound, composition and application thereof | 北京范恩柯尔生物科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115894497-A | Imidazopyrimidine compounds, and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-8541531-B2 | Anti-bleed compounds, compositions and methods for use thereof | DESIGNER MOLECULES, INC. | 2013-09-24 | — | — | US | disclosed |
| US-20110017400-A1 | ANTI-BLEED COMPOUNDS, COMPOSITIONS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2009117729-A2 | ANTI-BLEED COMPOUNDS, COMPOSITIONS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-0938842-B1 | Sustained release pheromone dispenser | SHINETSU CHEMICAL CO (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-6355236-B2 | Sustained release pheromone formation | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-20010053372-A1 | SUSTAINED RELEASE PHEROMONE FORMATION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2001-12-20 | — | — | US | disclosed |
| EP-0938842-A1 | Sustained release pheromone dispenser | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1999-09-01 | — | — | EP | disclosed |
| WO-1992009561-A1 | NEW AMIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110017400-A1 | ANTI-BLEED COMPOUNDS, COMPOSITIONS AND METHODS FOR USE THEREOF | ICAM1, ITGA5, ITGB5 | TSHR 4810/4885THRB 4373/4885FAAH 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.